Jasper Therapeutics Highlights Briquilimab at Major Congress
Jasper Therapeutics, Inc. (Nasdaq: JSPR), a leading clinical-stage biotechnology firm, has recently announced significant developments regarding their promising therapy, briquilimab. This innovative antibody therapy specifically targets c-Kit (CD117) to tackle a range of mast cell-driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The company has received exciting news as four abstracts have been accepted for presentation at an upcoming congress focused on allergies and clinical immunology.
Details on the EAACI Congress 2025 Presentations
Jasper's team will showcase their research at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, which is scheduled to take place over several days. One of the highlights of their presentations will be the SPOTLIGHT Phase 1b/2a study, which evaluates the efficacy of briquilimab in patients with conditions like cold urticaria and symptomatic dermographism. These presentations represent a pivotal moment for Jasper, allowing them to share groundbreaking clinical data.
Initial Results from SPOTLIGHT Study
This critical research encompasses the initial results from the SPOTLIGHT study, a Phase 1b/2a dose escalation trial focusing on adults suffering from inducible urticaria who are still experiencing symptoms despite conventional antihistamine treatments. The oral presentation is set to occur during a key session dedicated to clinical trials in dermatology.
Impressive Findings on Briquilimab
In another intriguing abstract, the company will discuss how a single dose of briquilimab exhibits protective effects against inflammatory relapses induced by environmental allergens in animal models, which is a promising advance in treating dermal allergic reactions.
Updates on Chronic Spontaneous Urticaria
Furthermore, Jasper will present updated results that demonstrate briquilimab’s ability to provide rapid and clinically meaningful disease control in adults grappling with CSU. This presentation is particularly timely as it showcases the advancing understanding of their product.
Addressing Asthma Through Briquilimab
Finally, Jasper is set to unveil findings related to the interaction of briquilimab with cigarette smoke and allergens in exacerbating asthma symptoms. With a strong focus on mast cell targeting, this research sheds light on the potential for briquilimab to manage chronic asthma more effectively.
About Jasper Therapeutics
Founded on a mission to advance treatment options for chronic mast cell diseases, Jasper Therapeutics is at the forefront of biopharmaceutical innovation. Briquilimab stands out as a targeted aglycosylated monoclonal antibody uniquely designed to inhibit the signaling pathway of mast cells by disrupting the binding of stem cell factor to KIT. This results in reduced mast cell viability and addresses the underlying cause of mast cell-driven inflammatory diseases.
The company is aggressively advancing its clinical studies in various indications, confident in briquilimab's established safety and efficacy profile demonstrated in previous research involving both patients and healthy participants. The positive outcomes lend credence to the promise that briquilimab holds for those afflicted by CSU, CIndU, and asthma.
Frequently Asked Questions
What is briquilimab?
Briquilimab is an antibody therapy developed by Jasper Therapeutics that targets c-Kit (CD117) to treat mast cell-driven diseases.
What diseases does briquilimab aim to address?
It focuses on conditions like chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.
Where will the presentations take place?
The presentations are scheduled to occur at the EAACI Annual Congress in Glasgow.
What type of data will Jasper be presenting?
The company will share initial clinical data from their ongoing studies demonstrating briquilimab's effects in adults with mast cell diseases.
Is briquilimab currently available for patients?
While actively in clinical trials, briquilimab is not yet available for general patient use, pending further results and regulatory approvals.
